The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Gut hormones and appetite regulation
Abstract
Purpose of review Various gut hormones interact with the brain through delicate communication, thereby influencing appetite and subsequent changes in body weight. This review summarizes the effects of gut hormones on appetite, with a focus on recent research. Recent findings Ghrelin is known as an orexigenic hormone, whereas glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK), postprandial peptide YY (PYY), and oxyntomodulin (OXM) are known as anorexigenic hormones. Recent human studies have revealed that gut hormones act differently in various systems, including adipose tissue, beyond appetite and energy intake, and even involve in high-order thinking. Environmental factors including meal schedule, food contents and quality, type of exercise, and sleep deprivation also play a role in the influence of gut hormone on appetite, weight change, and obesity. Recently published studies have shown that retatrutide, a triple-agonist of GLP-1, GIP, and glucagon receptor, and orforglipron, a GLP-1 receptor partial agonist, are effective in weight loss and improving various metabolic parameters associated with obesity. Summary Various gut hormones influence appetite, and several drugs targeting these receptors have been reported to exert positive effects on weight loss in humans. Given that diverse dietary and environmental factors affect the actions of gut hormones and appetite, there is a need for integrated and largescale long-te…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In Phase 1 pharmacokinetic studies conducted in healthy participants, no clinically meaningful elevations in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or total bilirubin were observed following single or multiple ascending doses of orforglipron, indicating an absence of acute hepatocellular or cholestatic toxicity [41,63,67].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [63]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“In addition, they have been reported to exert protective effects against cardiovascular diseases in certain populations] [40,41].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“The dual-acting GLP-1 and GIP receptor agonist tirzepatide has been reported to be more effective for weight reduction than classical GLP-1R agonists [42,43].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GLP-1 GLP-1, which is mainly synthesized by L cells, stimulates insulin release and inhibits glucagon secretion from pancreatic -cells via GLP-1 receptor [19].”
BackgroundA role for ghrelin in the central regulation of feeding
Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001) · Nature · doi:10.1038/35051587 · Cited by 3,443
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“The dual-acting GLP-1 and GIP receptor agonist tirzepatide has been reported to be more effective for weight reduction than classical GLP-1R agonists [42,43].”
BackgroundA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Cited by
Flavor and Well‐Being: A Comprehensive Review of Food Choices, Nutrition, and Health Interactions
Hossain, M. S., Wazed, M. A., Asha, S., Hossen, M. A., Fime, S. N. M., Teeya, S. T., Jenny, L. Y., Dash, D., & Shimul, I. M. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70276 · Cited by 69
Marco, M. L., Cunningham, M., Bischoff, S. C., Clarke, G. A., Delzenne, N. M., Lewis, J., Meisel, M., Merenstein, D. J., O’Toole, P. W., Staudacher, H. M., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01176-x · Cited by 58
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Li, S., Liu, M., Han, Y., Liu, C., Cao, S., Cui, Y., Zhu, X., Wang, Z., Liu, B., & Shi, Y. (2024) · mSystems · doi:10.1128/msystems.01015-24 · Cited by 25
Baccari, M. C., Vannucchi, M. G., & Idrizaj, E. (2024) · Nutrients · doi:10.3390/nu16183069 · Cited by 11
Metadata
- Authors
- Hong, S.-H., & Choi, K. M.
- Affiliations
- Ewha Womans University (KR)
- Korea University (KR)
- Corresponding author
- Choi, Kyung Mook
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2024-03-21
- Volume
- 31
- Issue
- 3
- Pages
- 115-121
- ISSN
- 1752-296X (ISSN-L)
- 1752-2978
- OpenAlex
- W4393045479
- Cited by
- 35
- References
- 55
- Citations by year
- 2026: 23 · 2025: 8 · 2024: 4
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- gastrointestinal hormones, appetite regulation, ghrelin, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, cholecystokinin, peptide YY, oxyntomodulin, anorexigenic hormones, orexigenic hormones, obesity, weight loss, retatrutide, orforglipron, meal timing, sleep deprivation, physical activity, adipose tissue
- MeSH terms
- Animals, Appetite, Appetite Regulation, Cholecystokinin, Gastric Inhibitory Polypeptide, Gastrointestinal Hormones, Humans, Obesity, Peptide YY, Glucagon-Like Peptide 1, Oxyntomodulin, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut hormones and appetite regulation. https://app.cochat.ai/papers/10.1097/med.0000000000000859
- The paper
- Hong, S.-H., & Choi, K. M. (2024). Gut hormones and appetite regulation. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/med.0000000000000859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.